CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02359019
NCT02359019Phase 2Completed
CompareCT.gov

Phase II Study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients

Barbara Ann Karmanos Cancer Institute·interventional·Posted Feb 9, 2015·Updated Oct 14, 2022

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab and Laboratory Biomarker Analysis for Extensive Stage Small Cell Lung Carcinoma. Completed, enrolled 45 participants across 5 sites.

Detailed Summary

This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy. Pembrolizumab may be effective in controlling small cell lung cancer for a longer period of time in patients with responsive or stable disease after completion of combination chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive Stage Small Cell Lung Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 9, 2015
Enrollment StartFeb 1, 2015
Primary CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.4 years ago

Interventions

Pembrolizumabbiological

Given IV

Laboratory Biomarker Analysisother

Correlative studies